Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 549-564

  Gubbins, Paul O ^a   Bowman, Jason L ^a   Penzak, Scott R ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; ORAL DRUG ADMINISTRATION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MEDLINE; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0031980419     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035-41.
2. Warnock DW. Fungal complications of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother 1995;36(suppl B):73-90.
3. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
4. Beyer J, Schwartz S, Heinemann V, Siegert W. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994;38:911-17.
5. Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273-84.
6. Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123:205-15.
7. Hunter AE, Haynes AP, Russell NH. Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother 1995;36(suppl B):119-33.
8. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
9. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of frequency in related and unrelated donor transplant recipients. Blood 1995;86:3979-86.
10. Reents S, Goodwin SD, Singh V. Antifungal prophylaxis in immunocompromised hosts. Ann Pharmacother 1993;27: 53-60.
11. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969;1:598-9.
12. Verfaillie C, Weisdorf D, Haake R, Hostettler M, Ramsay NK, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
13. Roll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993;17(suppl 2):S322-8.
14. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993;94:577-82.
15. Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987;83:709-18.
16. Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a twenty-year period. Infect Control Hosp Epidemiol 1989;10:299-305.
17. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66.
18. Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993;14:131-9.
19. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990;17(suppl 6):10-13.
20. Arnow PM, Anderson RL, Mainous PD, Smith EJ. Pulmonary aspergillosis during hospital renovation. Am Rev Respir Dis 1978;118:49-53.
21. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982; 116:430-7.
22. Working Party of the British Society for Antimicrobial Chemotherapy Report. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1994;32:5-21.
23. Anaissie, EJ, Monson TP, Penzak SR, et al. Opportunistic fungi recovered from hospital water systems. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1997.
24. Rhame FS, Streifel AJ, Kersey JH, McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med 1984;76(suppl 5A):42-52.
25. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;91:484-92.
26. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497-503.
27. Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-503.
28. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988;158:1046-55.
29. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-14.
30. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
31. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin B prophylaxis in high-risk patients. J Clin Oncol 1994;12:827-34.
32. Tollemar J, Ringdén O, Anderson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-82.
33. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother 1989;33:362-8.
34. Christiansen KJ, Bernard EM, Gold J, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis 1985;152(5):1037-43.
35. Block ER, Bennett JE, Livoti LG, Klein WJ, MacGregor RR, Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med 1974;80:613-17.
36. Morgan DJ, Ching MS, Raymond K, et al. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983;34:248-53.
37. Brajtburg JS, Elberg S, Bolard J, et al. Interaction of plasma proteins and lipoproteins with amphotericin B. Br J Infect Dis 1984;149:986-97.
38. Jeffery GM, Beard ME, Ikram RB, et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991;90:685-92.
39. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytic patients. Bone Marrow Transplant 1990;5:403-6.
40. Behre GF, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995;71:287-91.
41. Heinemann V, Schwartz S, Behre G, Beyer J. Aerosolized amphotericin B for prevention of invasive Aspergillus infections in neutropenic patients: results of a prospective randomized trial. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1997.
42. Walsh T, Bodensteiner D, Hiemenz J, et al. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1997.
43. Cagnono PJ, Grethlein S, Korones DN, et al. Improved safety and efficacy of AmBisome (liposomal amphotericin B) compared with amphotericin B in the empirical treatment of febrile neutropenic patients undergoing bone marrow transplantation. Blood 1997;90(suppl 1, pt 1 of 2):420a.
44. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
45. Wingard JR, Walker RC. Efficacy of amphotericin B lipid complex in the treatment of bone marrow transplant recipients with life-threatening systemic mycoses [abstr]. Blood 1994;84(suppl):486A.
46. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
47. Chanrasekar PH, Gatney CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994;40:136-43.
48. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-84.
49. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37(9): 1847-9.
50. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
51. Laverdiere M, Rotstein C, Bow EJ, Carr D, Moghaddam N, Ioannou S. The impact of fluconazole prophylaxis and subsequent infection in cancer neutropenic patients. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1997.
52. Shaw MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy, and cytotoxic drugs on intestinal structure and function. Cancer Treat Rev 1979;6:141-51.
53. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(suppl 1):S94-9.
54. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, DeBeule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(suppl 1):103-8.
55. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
56. Persat F, Marzullo C, Guyotat D, Rochet MJ, Piens MA. Plasma itraconazole concentrations in neutropenic patients after repeated high dose treatment. Eur J Cancer 1992;28: 838-41.
57. Gubbins PO, Gurley BJ, Arnold E, et al. A study to determine the pharmacokinetics (PK) of itraconazole (ITZ) and its metabolite, hydroxyitraconazole (OH-ITZ) in allogeneic bone marrow transplant (BMT) recipients. In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1995.
58. Prentice AG, Warnock DW, Johnson SA, Taylor PC, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34:247-52.
59. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia. J Antimicrob Chemother 1995;36:657-63.
60. Morgenstern GR, Prentice AG, Prentice HG, et al. Itraconazole oral solution vs. fluconazole suspension for antifungal prophylaxis in neutropenic patients. In: Programs and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1996.